Afrezza denied for failing step therapy by Humana?

Humana's specific coverage criteria for afrezza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Afrezza Under Step Therapy

Step therapy — sometimes called "fail first" — is Humana's policy of requiring patients to try and document failure on one or more formulary-preferred insulin products before Afrezza (inhaled insulin) will be covered. Denials under this policy occur when the claim or PA request does not include documentation showing the patient has already tried the required prior-step medications, or when the documentation is present but the reviewer determines the prior trials were not adequate in duration or dose, or that the reason for stopping was not clinically compelling.

## Why This Denial Is Appealable

Step-therapy denials are among the most commonly overturned drug denials on appeal. Many states have enacted step-therapy exception laws requiring plans to waive the step-therapy requirement when a prior-step drug was tried and failed, is clinically contraindicated, or would cause significant harm. Federal plans under ERISA must at minimum provide a full-and-fair review under Section 503. Under ACA Section 2719 you are entitled to internal appeal followed by independent external review by a federally accredited IRO. The external-review window is typically around four months from the final internal denial; expedited review is available when delay would jeopardize health.

## Building the Step-Therapy Exception

1. Request Humana's step-therapy criteria for Afrezza in writing. The criteria will name the specific products that must be tried and the duration or other conditions required for each. Every argument in your appeal should map to these criteria by name.

2. Document each prior insulin trial exhaustively. For every formulary insulin the patient has used, record: - Drug name and formulation - Dates of use (start and stop) - Reason for discontinuation or modification (inadequate glycemic control, recurrent hypoglycemia, injection-site complications, comorbid condition, etc.) - Supporting chart entries, glucose logs, or lab values

3. If prior-step drugs have not been tried, argue clinical exception. The prescriber must explain why requiring a trial of the step-therapy drug would be clinically inappropriate — for example, because a comorbid condition makes injectable insulin higher risk, because the patient has documented needle phobia or injection-site issues, or because of another individualized clinical factor. The explanation must be grounded in chart documentation.

4. Confirm FDA label eligibility. The FDA prescribing information for Afrezza defines the approved population. Confirm with the prescriber that every criterion in the label is met and is documented in the chart.

5. Check applicable state step-therapy exception law. Many states require plans to process step-therapy exception requests within defined timeframes and to grant exceptions on documented prior failure or clinical contraindication. Identify whether your state's law applies to this plan and cite it in the appeal.

6. Include a detailed prescriber medical-necessity letter. The letter must go step by step through Humana's criteria, citing specific chart facts for each. It should address both why prior-step drugs were inadequate and why Afrezza is medically necessary for this patient.

## Key Documents

• Humana's step-therapy criteria for Afrezza (current version)
• FDA prescribing label for Afrezza
• Complete prior insulin history with dates, outcomes, and supporting chart notes
• Prescriber's individualized step-therapy exception and medical-necessity letter
• Relevant glucose logs, lab results, and clinical notes
• Applicable state step-therapy exception law citation if relevant

## Timeline

• Internal appeal: File within the period on the denial notice (often 180 days). Decision typically 30 days; 72 hours expedited.
• External review: Request within approximately four months of final internal denial. The IRO applies clinical standards independently of Humana's formulary preferences.